Indian pharmaceutical companies are gearing up to introduce low-cost generic versions of semaglutide—the active ingredient in Novo Nordisk’s blockbuster drugs Ozempic (for diabetes) and Wegovy (for weight loss)—following the expiration of the key patent in India.
The patent on semaglutide expires on March 20, 2026, which will pave the way for multiple domestic pharmaceutical manufacturers to launch affordable generic versions. This development is expected to significantly reduce prices, potentially by 40-60% or more compared to the branded medications, making these popular GLP-1 receptor agonist treatments more accessible amid rising demand for medications for treating diabetes and obesity.
Major pharma companies like Zydus Lifesciences, Dr. Reddy’s Laboratories, and others are preparing launches, with some aiming for monthly costs as low as ₹3,000–₹4,000 (or even lower as competition intensifies). Industry experts anticipate a flood of nearly 50 generic brands entering the market soon after the expiry, which could completely alter the pricing dynamics not just in India but also in other markets for semaglutide-based therapies.
While Novo Nordisk has recently launched Ozempic in India at a relatively lower entry price (around $97/month for certain doses), the company maintains its focus on branded trust rather than immediate price cuts in response to generics. In contrast, the U.S. and many other markets will see patent protections last much longer (into the 2030s), delaying widespread generic availability there.
This shift highlights India’s role as a global hub for affordable but good quality generic medicines, potentially expanding access to these transformative medications for millions in low- and middle-income countries across the globe.
